Safety and Short-term Outcomes of High-Dose Erythropoietin in Preterm Infants With Intraventricular Hemorrhage: The EpoRepair Randomized Clinical Trial.

ABSTRACT:

Importance

Intraventricular hemorrhage (IVH) is a major cause of neonatal morbidity and mortality in preterm infants without a specific medical treatment to date.

Objective

To assess the safety and short-term outcomes of high-dose erythropoietin in preterm infants with IVH.

Design, setting, and participants

Between April 1, 2014, and August 3, 2018, a randomized double-blind clinical trial enrolled 121 preterm infants (gestational age <32 weeks or birth weight <1500 g) aged 8 or less days with moderate to severe IVH identified by cerebral ultrasonography from 8 Swiss and Austrian tertiary neonatal units. Statistical analyses were performed between October 1, 2019, and September 12, 2022.

Interventions

Infants received intravenous high-dose erythropoietin (2000

SUBMITTER: Wellmann S 

PROVIDER: S-EPMC9719050 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature